Resmetirom Prior Authorization and Quantity Limits
Customize your policy alerts
Sign up for all prime_therapeutics policy alerts
Know when prime_therapeutics releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage of Rezdiffra (resmetirom) tablets for Boeing commercial members, including initial authorization, renewal, and quantity-limit exceptions. Coverage requires clinical criteria for noncirrhotic NASH/MASH with moderate-to-advanced fibrosis or another FDA-labeled indication, along with applicable safety, specialist, and documentation requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.